Diabetes

Johnson & Johnson is big winner in CVS diabetes formulary changes

Johnson & Johnson is big winner in CVS diabetes formulary changes

By

CVS Health will remove Lilly's Jardiance in favor of J&J's Invokana.

Five things for pharma marketers to know: Thursday, July 27, 2017

Five things for pharma marketers to know: Thursday, July 27, 2017

By

Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug

Five things for pharma marketers to know: Thursday, July 20, 2017

Five things for pharma marketers to know: Thursday, July 20, 2017

By

About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1

Diabetes drugmakers partner with mobile startups to boost patient engagement

Diabetes drugmakers partner with mobile startups to boost patient engagement

By

Novo Nordisk and Roche are two examples of drugmakers that are turning to digital-health startups to better engage with patients and mine valuable real-world evidence.

Five things for pharma marketers to know: Thursday, July 13, 2017

Five things for pharma marketers to know: Thursday, July 13, 2017

By

AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge

Five things for pharma marketers to know: Wednesday, July 5, 2017

Five things for pharma marketers to know: Wednesday, July 5, 2017

By

Amgen and Teva raise prices of leukemia drugs twice this year; Roche acquires diabetes app; docs use Snapchat to share patient scans

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

By

Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

By

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

By

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

Five things for pharma marketers to know: Thursday, April 13, 2017

Five things for pharma marketers to know: Thursday, April 13, 2017

By

Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments

Five things for pharma marketers to know: Friday, April 7, 2017

Five things for pharma marketers to know: Friday, April 7, 2017

By

The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test

Rick Altinger, Glooko

Rick Altinger, Glooko

Rick Altinger is CEO of Glooko.

Sean Duffy, Omada Health

Sean Duffy, Omada Health

Sean Duffy is CEO of Omada Health.

Five things for pharma marketers to know: Monday, March 20, 2017

Five things for pharma marketers to know: Monday, March 20, 2017

By

Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

By By

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

By

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

Five things for pharma marketers to know: Tuesday, January 31, 2017

Five things for pharma marketers to know: Tuesday, January 31, 2017

By

Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing

Five things for pharma marketers to know: Friday January 27, 2017

Five things for pharma marketers to know: Friday January 27, 2017

By

BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup

When it comes to diabetes, will marketers break with tradition?

When it comes to diabetes, will marketers break with tradition?

By

That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"

Top 25 metabolic brands, by sales, 2015-2016

Top 25 metabolic brands, by sales, 2015-2016

Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.

Lexicon developing type 1 diabetes treatment with Sanofi

Lexicon developing type 1 diabetes treatment with Sanofi

By

Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.

Five things for pharma marketers to know: Wednesday, December 28, 2016

Five things for pharma marketers to know: Wednesday, December 28, 2016

By

Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013

Five things for pharma marketers to know: Wednesday, December 21, 2016

Five things for pharma marketers to know: Wednesday, December 21, 2016

By

GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores

Eli Lilly will discount its insulins to some patients

Eli Lilly will discount its insulins to some patients

By

Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.

Five things for pharma marketers to know: Tuesday, December 13, 2016

Five things for pharma marketers to know: Tuesday, December 13, 2016

By

Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant

How Digital Innovation is Influencing Diabetes Care

How Digital Innovation is Influencing Diabetes Care

Adherence is one of the biggest challenges physicians face in diabetes management.

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

By

Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

By

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Lilly's branded app for Trulicity looks to address adherence

Lilly's branded app for Trulicity looks to address adherence

By

Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.